Comparing Pasithea Therapeutics (KTTA) and Its Competitors

Institutional & Insider Ownership

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 16.3% of Pasithea Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Pasithea Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics’ rivals have a beta of 0.99, indicating that their average share price is 1% less volatile than the S&P 500.

Valuation & Earnings

This table compares Pasithea Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pasithea Therapeutics	N/A	-$13.90 million	-0.07
Pasithea Therapeutics Competitors	$888.67 million	-$47.68 million	-1.86

Pasithea Therapeutics’ rivals have higher revenue, but lower earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Pasithea Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-88.14%	-81.21%
Pasithea Therapeutics Competitors	-1,345.60%	-585.81%	-28.37%

Summary

Pasithea Therapeutics beats its rivals on 5 of the 9 factors compared.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.